Abstracts tagged "Inflammation"

Abstract Number: 0916 • ACR Convergence 2021
Disease Activity and Inflammation in Axial Spondyloarthritis Patients Who Did Not Experience Flares Following Certolizumab Pegol Withdrawal, Dose Reduction or Dose Continuation
Lianne Gensler¹, Xenofon Baraliakos², Lars Bauer³, Bengt Hoepken³, Thomas Kumke³, Mindy Kim⁴ and Robert Landewé⁵, ¹Department of Rheumatology, University of California San Francisco, San Francisco, CA, ²Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ³UCB Pharma, Monheim am Rhein, Germany, ⁴UCB Pharma, Smyrna, GA, ⁵Amsterdam Rheumatology & Clinical Immunology Center, Amsterdam, Netherlands; Zuyderland MC, Heerlen, Netherlands
Background/Purpose: C-OPTIMISE was a phase 3b study investigating certolizumab pegol (CZP) maintenance dose continuation, reduction or withdrawal following achievement of sustained remission in patients with…
Abstract Number: 1196 • ACR Convergence 2021
Morning Stiffness Already Associates with Systemic Inflammation and Subclinical Joint Inflammation in the Pre-RA Phase of Arthralgia
Doortje Krijbolder¹, Fenne Wouters¹, Elise van Mulligen² and Annette H.M van der Helm-van Mil¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Morning stiffness (MS) is characteristic for Rheumatoid Arthritis (RA) and associates with markers of systemic and local inflammation in RA-patients. In patients with arthralgia,…
Abstract Number: 1625 • ACR Convergence 2021
Clinical Characteristics of Multisystem Inflammatory Syndrome in Children: A Provincial Cohort
Herman Tam¹, Alison Lopez², Mona Patel², Jonathan Rayment³, Lori Tucker⁴ and Catherine Biggs⁵, ¹Stollery Children's Hospital, University of Alberta, Edmonton, AB, Canada, ²British Columbia Children's Hospital, University of British Columbia, Vancouver, BC, Canada, ³British Columbia Children’s Hospital, University of British Columbia, Vancouver, BC, Canada, ⁴BC Children's Hospital, Vancouver, BC, Canada, ⁵[email protected], Vancouver, BC, Canada
Background/Purpose: Multisystem Inflammatory Syndrome in Children (MIS-C) is a post-infectious complication of COVID-19 infection with overlapping features of Kawasaki Disease (KD) and Toxic Shock Syndrome…
Abstract Number: L03 • ACR Convergence 2020
Efficacy and Safety of Deucravacitinib (BMS-986165), an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Active Psoriatic Arthritis: Results from a Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial
Philip Mease¹, Atul Deodhar², Désirée van der Heijde³, Frank Behrens⁴, Alan Kivitz⁵, Jonghyeon Kim⁶, Shalabh Singhal⁶, Miroslawa Nowak⁶ and Subhashis Banerjee⁶, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Oregon Health & Science University, Portland, OR, ³Leiden University Medical Center, Leiden, Netherlands, ⁴CIRI/Rheumatology and Fraunhofer Institute IME, Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ⁵Department of Rheumatology, Altoona Center for Clinical Research, Duncansville, PA, ⁶Bristol Myers Squibb, Princeton, NJ
Background/Purpose: Tyrosine kinase 2 (TYK2) is an intracellular kinase that mediates signaling by key cytokines involved in psoriatic arthritis (PsA) pathophysiology. Deucravacitinib (BMS-986165) is a…
Abstract Number: L06 • ACR Convergence 2020
Mavrilimumab (anti GM-CSF Receptor α Monoclonal Antibody) Reduces Time to Flare and Increases Sustained Remission in a Phase 2 Trial of Patients with Giant Cell Arteritis
Maria C. Cid¹, Sebastian Unizony², Lara Pupim³, Fang Fang⁴, Joseph Pirrello³, Ai Ren⁴, Manoj Samant⁴, Teresa Zhou⁴ and John F Paolini⁴, ¹Hospital Clinic Barcelona, Barcelona, Spain, ²Massachusetts General Hospital, Boston, MA, ³Kiniksa Pharmaceuticals, Lexington, MA, ⁴Kiniksa Pharmaceuticals, Lexington
Background/Purpose: T helper (Th)1 and Th17 lymphocytes play a role in the pathogenesis of giant cell arteritis (GCA). Current treatments (e.g., corticosteroids and tocilizumab) target…
Abstract Number: 0073 • ACR Convergence 2020
A Cross-Species Map of Neutrophil Inflammatory Responses
Felix Radtke¹, Frank Huang², Peter Nigrovic³ and Ricardo Grieshaber-Bouyer⁴, ¹Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany, Heidelberg, Baden-Wurttemberg, Germany, ²Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany, Darmstadt, Baden-Wurttemberg, Germany, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ⁴Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Heidelberg, Germany
Background/Purpose: Neutrophils are important mediators of immune defense as well as key protagonists in immune-mediated disease. How these cells adapt differently to sterile and septic…
Abstract Number: 0528 • ACR Convergence 2020
The Complex Relationship Between C4b Binding Protein, Warfarin and Antiphospholipid Antibodies
Giorgia Grosso¹, Kerstin Sandholm², Aleksandra Antovic¹, Iva Gunnarsson¹, Agneta Zickert¹, Anna Vikerfors³, Lennart Truedsson⁴, Maria Bruzelius¹, Bo Nilsson⁵, Kristina Nilsson Ekdahl⁵ and Elisabet Svenungsson¹, ¹Karolinska University Hospital, Stockholm, Sweden, ²Linnaeus Center for Biomaterials Chemistry, Linnaeus University, Kalmar, Sweden, ³Swedish Medical Products Agency, Uppsala, Sweden, ⁴Lunds University, Lund, Sweden, ⁵Uppsala University, Uppsala, Sweden
Background/Purpose: C4b Binding Protein (C4BP) is the main inhibitor of the classical complement pathway. Both β2glycoprotein-I (β2GPI), the main antigen in the antiphospholipid syndrome (APS),…
Abstract Number: 0772 • ACR Convergence 2020
Modification of THP-1 Cells with Malondialdehyde-Acetaldehyde Increases Cellular Calcium Load Rendering Cells Susceptible to Citrullination of Self-Proteins
Nozima Aripova¹, Michael Duryee¹, Xiarepati Tieliwaerdi¹, Xiaoting Jiang¹, Lynell Klassen², James O'Dell¹, Bryant England¹, Ted Mikuls¹ and Geoffrey Thiele¹, ¹University of Nebraska Medical Center, Omaha, NE, ²Univerisity of Nebraska Medical Center, Omaha, NE
Background/Purpose: The post translational modification of self-proteins with malondialdehyde-acetaldehyde (MAA) has been shown to alter protein function and antibodies to MAA are increased in both…
Abstract Number: 1041 • ACR Convergence 2020
Pharmaco-epidemiology of Non-infectious Ocular Inflammatory Disease in a Tertiary Academic Center
Sanjeev Patil¹, Justine Cheng², Lorraine Provencher³ and Scott Vogelgesang⁴, ¹University of Vermont Medical Center, Essex Junction, VT, ²University of Iowa Hospitals and Clinics, Iowa City, IA, ³Cincinnati Eye Institute, Cincinnati, OH, ⁴University of Iowa Hospitals and Clinics, Iowa City, IA
Background/Purpose: Non-Infectious Ocular inflammatory disease (OID) is a group of immune-mediated diseases involving the ocular surface, uveal tract, retina, optic nerve, and peri-orbital tissue. Patients…
Abstract Number: 1400 • ACR Convergence 2020
cAMP Response Element Modulator (CREM)α Promotes PD-1- effector CD4+ T Cells in Psoriasis and Psoriatic Arthritis
Sigrun Hofmann¹, Franz Kapplusch², Susanne Abraham³, Sarah Northey², Susanne Russ¹, Felix Schulze¹, Anna Surace⁴ and Christian Hedrich⁵, ¹Klinik und Poliklinik für Kinder- und Jugendmedizin, Universitätsklinikum Carl Gustav Carus, TU Dresden, Dresden, Germany., Dresden, Germany, ²Department of Women's and Children's Health, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom., Liverpool, United Kingdom, ³Klinik und Poliklinik für Dermatologie, Universitätsklinikum Carl Gustav Carus, TU Dresden, Dresden, Germany., Dresden, Germany, ⁴Centre for Experimental Medicine and Rheumatology, Queen Mary University of London, Liverpool, United Kingdom, ⁵University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Psoriasis is a systemic autoimmune/inflammatory condition that primarily affects the skin, but also other organ systems. Effector CD4+ T lymphocytes have been identified as…
Abstract Number: 1796 • ACR Convergence 2020
A Panel of Urinary Proteins Predicts Active Lupus Nephritis and Response to Rituximab Treatment
Jennifer Davies¹, Emil Carlsson¹, Angela Midgley¹, Eve Smith¹, Ian Bruce², Michael Beresford¹ and Christian Hedrich³, ¹Department of Women's and Children's Health, Institute of Life Course and Medical Sciences, Liverpool, England, United Kingdom, ²Centre for Epidemiology Versus Arthritis, The University of Manchester and NIHR Manchester Biomedical Research Centre, Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom, ³University of Liverpool, Liverpool, United Kingdom
Background/Purpose: Approximately 30% of patients with adult-onset systemic lupus erythematosus (SLE) develop lupus nephritis (LN). Presence and/or severity of LN are currently assessed by renal…
Abstract Number: 0075 • ACR Convergence 2020
CD209+/CD14+ Dendritic Cells Characterization in Rheumatoid versus Psoriasis Arthritis Patients
Viviana Marzaioli¹, Achilleas Floudas², Mary Canavan¹, Siobhán Wade³, Kieran Murray⁴, Ronan Mullan⁵, Conor Hurson⁶, Douglas Veale⁷ and Ursula Fearon¹, ¹Molecular Rheumatology, Trinity College Dublin, Dublin, Dublin, Ireland, ²Molecular Rheumatology Trinity Biomedical Sciences Institute, Dublin, Dublin, Ireland, ³Trinity College Dublin, Dublin, Ireland, ⁴Saint Vincent's University Hospital, Dublin 4, Dublin, Ireland, ⁵Adelaide and Meath Hospital, Dublin, Dublin, Ireland, ⁶St Vincents University Hospital, UCD, Dublin, Dublin, Ireland, ⁷EULAR Centre for Arthritis and Rheumatic Diseases, St Vincents University Hospital, UCD, Dublin, Dublin, Ireland
Background/Purpose: Dendritic cells (DCs) are a heterogeneous population of professional antigen-presenting cells which are at the interface between innate and adaptive immunity. There are different…
Abstract Number: 0558 • ACR Convergence 2020
Statin Use Pattern in Patients with Inflammatory Joint Disease in a Single Site VA Medical Center
Lenche Kostadinova¹, Sofi Damjanovska², Angela Gupta³, Ibtissam Gad⁴, Sameena Syed⁴, Alyssa Lange⁵, Corinne Kowal⁶, Carey Shive⁷, Christopher Burant⁴, Brigid Wilson⁴, David Canaday⁴, David Zidar⁸, Donald Anthony⁹ and Maya Mattar¹⁰, ¹(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Highland Heights, OH, ²(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH, ³(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, ⁴(1) Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, ohio, ⁵Case Western Reserve University, Cleveland, ⁶Case western reserve university/Cleveland VA Medical Center, ohio, ⁷(2) Department of Pathology, Case Western Reserve University, ohio, ⁸Case Western Reserve University/Cleveland VA Medical Center, Cleveland, ⁹Case Western Reserve University/Cleveland VA Medical Center/MetroHealth Medical Center, Cleveland, OH, ¹⁰Department of Medicine, VA Medical Center and VA GRECC, Case Western Reserve University, Cleveland OH, Cleveland, OH
Background/Purpose: Patients with inflammatory joint disease, including rheumatoid arthritis (RA), psoriatic arthritis (PsA) and ankylosing spondylitis (AS) carry increased risk of cardiovascular disease (CVD). Mechanisms…
Abstract Number: 0776 • ACR Convergence 2020
The Influence of Adipokine Profile and Periodontal Infection in Early Stages of Rheumatoid Arthritis and First-degree Relatives
Consuelo Romero-Sanchez¹, Juliette De Avila², Jeimmy Andrea Chaparro-Sanabria³, Philipe Chalem Choueka⁴, Juan Manuel Bello-Gualtero⁵, Alejandro Ramos-Casallas², Lorena Chila-M² and Wilson Bautista-Molano⁶, ¹Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada / Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada /Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, ²Universidad El Bosque, Cellular and Molecular Immunology Group -InmuBo-, School of Dentistry, Bogotá D.C., Colombia, ³Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, ⁴Fundacion Instituto de Reumatología Fernando Chalem, Universidad El Rosario, Bogotá D.C., Colombia, ⁵Hospital Militar Central, Rheumatology and Immunology Department, Universidad Militar Nueva Granada/ Clinical Immunology Group, Hospital Militar Central, School of Medicine, Universidad Militar Nueva Granada, Bogotá D.C., Colombia, ⁶University Hospital Fundación Santa Fé de Bogotá and Universidad El Bosque, Bogotá, Colombia
Background/Purpose: Early RA (eRA) patients have a significant incidence of periodontal inflammation and overweight/obesity. A similar degree of disease activity, functional disability and health-related quality…
Abstract Number: 1043 • ACR Convergence 2020
Ocular Scleral Pathology and Immune-Mediated Inflammatory Diseases. Study of 170 Patients from a Single Universitary Center
Lara Sanchez-Bilbao¹, Inigo Gonzalez-Mazon², José Luis Martín-Varillas³, David Martinez-Lopez⁴, Carmen Alvarez-Reguera¹, Alba Herrero Morant¹, Rosalia Demetrio-Pablo¹, Vanesa Calvo-Río¹, Miguel Ángel González-Gay⁵ and Ricardo Blanco¹, ¹Hospital Universitario Marques de Valdecilla, Santander, Spain, ²Hospital Universitario Marques de Valdecilla, Bezana, Spain, ³Hospital Sierrallana, Torrelavega, Spain, ⁴Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, ⁵Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain
Background/Purpose: Ocular scleral pathology (OSP) includes episcleritis and scleritis. Episcleritis is generally a benign disease with a self-limited course, while scleritis is a more severe…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.